The efficacy question for exercise on the bone surrogate in postmenopausal women — and the surrogate discipline that gates what the answer is worth. The safety page (Exercise Safety in Osteoporosis) asks whether exercise breaks a fragile skeleton; the falls page (Exercise for Preventing Falls in Older Adults) asks whether it prevents the fall that fractures one. This page asks the third, distinct decision: does loading the skeleton raise bone mineral density (BMD), and — the load-bearing question — does a BMD gain actually mean fewer fractures, the outcome a person cares about. First source held: Mohebbi 2023, a gold updated SR-MA (80 studies, 94 training and 80 control groups, 5581 participants pooled) of controlled exercise trials >= 6 months, applying the inverse-heterogeneity (IVhet) model. (Mohebbi et al., 2023)
The effect on the surrogate: real, positive, small-to-moderate
Exercise raises BMD at all three sites, but the effect is modest and the magnitude framing is the source’s own:
- Lumbar spine (LS): SMD 0.29 (95% CI 0.16-0.42); heterogeneity substantial (I2 = 68%), and publication-bias/small-study evidence HIGH at this site.
- Femoral neck (FN): SMD 0.27 (95% CI 0.16-0.39).
- Total hip (TH): SMD 0.41 (95% CI 0.30-0.52); heterogeneity low (I2 = 20%), publication-bias evidence negligible.
The authors classify the size plainly: «the average SMD for BMD effects on LS, FN, and TH can be classified as moderate at best (i.e., 0.2 to 0.5)» (Mohebbi et al., 2023). So the honest headline is a small positive standardized effect on a surrogate, best-evidenced and cleanest at the total hip, and weakest (noisiest, most bias-suspect) at the lumbar spine.
The moderators are all NULL — the for whom question does not separate
The update’s stated purpose was to find effect modification — who benefits more. It found none. Across three pre-specified group comparisons the exercise effect on BMD did not differ significantly (all p > .09):
- osteopenia/osteoporosis vs normal BMD (bone status),
- early vs late postmenopausal (menopausal status),
- predominantly supervised vs predominantly non-supervised programs.
This is a route-(b) null: the search for a subgroup with a larger relative BMD effect came up empty on the three axes most expected to modify it. It does not deny route-(a) stratification — absolute fracture benefit still scales with baseline fracture risk even when the relative BMD effect is flat (Baseline Risk and the Relative-Absolute Split) — but it removes the positive interaction evidence that would license personalizing the exercise prescription by bone or menopausal status. The high residual heterogeneity (I2 up to 68%) says trials differ a lot in effect, but the measured moderators do not explain it.
The load-bearing limit: BMD is a SURROGATE, and transmission to fracture is not shown here
(inferred from Mohebbi et al., 2023) — Mohebbi measures BMD, not fracture. BMD is a surrogate for the patient-important outcome (fracture, and downstream function/independence), and the whole surrogate discipline applies (Surrogate Outcomes). Two cautions run in opposite directions and both matter:
- BMD may UNDER-capture exercise’s true fracture benefit. Exercise prevents fractures through at least two channels, and BMD sees only one. The bone-loading channel (mechanostat: load raises BMD) is what this page measures; the falls channel (balance, strength, gait -> fewer falls -> fewer fractures) is largely BMD-independent and is where the larger fracture signal for older adults sits (Exercise for Preventing Falls in Older Adults: exercise cuts falls, RaR ~0.77). A BMD meta-analysis is structurally blind to that channel — the streetlight effect on the outcome side.
- A small statistical BMD gain may NOT transmit to meaningful fracture reduction. The corpus already holds a worked inversion of exactly the BMD->fracture link: GRADE’s handbook names «bone mineral density for fractures» as a proximate surrogate (rate down only one level), yet in the TRAVERSE testosterone RCT the surrogate rose while clinical fractures rose too (HR 1.43) -> Surrogate Outcomes. Proximity plus mechanism plus a consistently-moving marker were still not enough. That case is a different exposure (a drug, not loading) and cannot be transported to exercise, but it is the standing proof that a BMD gain is not self-evidently a fracture reduction.
(inferred from Mohebbi et al., 2023) The direct fracture-outcome evidence for exercise is not held here. Mohebbi’s own group reports it elsewhere — «the favorable effect of supervised exercise protocols on fracture» (Mohebbi et al., 2023) — but that SR is a separate source not yet held (an exercise -> fracture-incidence meta-analysis), needed to close the surrogate->outcome step for the loading channel.
The supervision discordance — surrogate silent, real outcome not
A sharp instance of why the surrogate can mislead: supervision made no significant difference to BMD in this meta-analysis (the null above), yet Mohebbi’s group argues supervision matters more for bone than for falls, and their separate fracture SR credits supervised protocols with the fracture benefit (Mohebbi et al., 2023). So a program feature that is null on the BMD surrogate may still bear on the patient-important outcome (adherence, dose fidelity, safety) — a caution against reading no BMD difference as no decision difference. (inferred from Mohebbi et al., 2023)
Confidence, and the non-independence caveat
confidence: medium, and the three legs are deliberately split:
- BMD-surrogate efficacy exists and is positive: well-evidenced (gold updated SR-MA, consistent across three sites, robust IVhet model). This leg alone would be high.
- Moderators: NULL / low — no effect modification shown on bone status, menopausal status, or supervision; do not personalize the prescription on them.
- Fracture transmission: low / uncertain — not measured here; the surrogate discipline and the in-corpus inversion cap what the BMD gain licenses. This is what pulls the page to medium.
Non-independence (binding). Mohebbi is the Erlangen/Kemmler group (Kemmler, von Stengel, Shojaa, Jakob among the authors) and is an explicit update of Shojaa et al. — «further evidence» in the source’s own words. It is therefore not independent (type-E) corroboration of the broader Shojaa/Kemmler exercise-bone literature; convergence across their reviews reflects a shared team, data pool, and method, and must not inflate confidence. The wiki holds no independent research group’s exercise-BMD meta-analysis yet — a genuine gap for the robustness of the surrogate effect.
The author’s own verdict on meta-analytic precision here
Notably, the source itself doubts that pooling delivers a prescription: «their practical application for deriving dedicated and reliable exercise recommendations is rather limited» (Mohebbi et al., 2023). The high between-trial heterogeneity means the mean SMD hides wide variation in what individual protocols achieve — the pooled number says exercise-in-general nudges BMD, not which program a person should do. The load/impact/dose specifics live in the programming frontier (Resistance Training Prescription - Load Sets and Frequency), kept peripheral by Layer-1.
Decision relevance
- The exposure is worth pulling, but size the rock honestly. For a postmenopausal woman, exercise produces a small positive BMD effect on a surrogate; its stronger fracture case rests on the falls channel it does not measure (Exercise for Preventing Falls in Older Adults) plus a separate, not-yet-held fracture SR. Frame the recommendation on the composite (bone + falls + strength + function), not on the BMD number alone.
- Non-substitutable by the obvious drug — for the pleiotropy, not the BMD. An antiresorptive (bisphosphonate) raises BMD and cuts fracture and would, for the bone-density outcome alone, shrink the exercise rock. But exercise is pleiotropic (falls, muscle, gait, cardiometabolic, mortality -> Muscle-Strengthening Activity and Mortality) and a single-channel drug does not substitute for those other-channel benefits — so the lever’s rank falls only for the BMD outcome the drug actually covers. The drug’s efficacy/limitations are not held in the fabric — a genuine G-gap (bisphosphonate/antiresorptive comparator); do not assert its effect as fact here, and the choice between lever and drug stays the person’s (Layer 3).
- Do not personalize the exercise prescription on bone or menopausal status — the moderator evidence is null; the stratifying variable that does work is baseline fracture risk (route (a), absolute benefit), which BMD/FRAX supplies as a prognostic input, not a treatment target.
- Menopause context: accelerated post-menopausal bone loss is one of the shifting levers (Menopause and the Shifting Levers); exercise is a modifiable counter-lever on the bone axis, weighted alongside the others there.